Design of a Multifunctional PLGA Nanoparticulate Drug Delivery System: Evaluation of its Physicochemical Properties and Anticancer Activity to Malignant Cancer Cells

Wang, Zhe; Chui, Wai Keung; Ho, Paul C.

doi:10.1007/s11095-009-9837-y

Cited by 96 publications

(57 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This integrin is recognized by the peptide sequence arginine-glycine-aspartic acid (RGD) [523,524]. Wang et al [525] angiogenic vessels [532,533]. The use of a tumor-homing peptide, iRGD, an RGD peptide that contains a tumor penetrating peptide (CendR or C-end rule), results in an optimized delivery of anticancer drugs deeply to the tumors.…”

Section: Peptidic Targetingmentioning

confidence: 99%

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Pérez-Herrero

Fernández‐Medarde

2015

European Journal of Pharmaceutics and Biopharmaceutics

1,460

754

View full text Add to dashboard Cite

Cancer is the second worldwide cause of death, exceeded only by cardiovascular diseases. It is characterized by uncontrolled cell proliferation and an absence of cell death that, except for hematological cancers, generates an abnormal cell mass or tumor. This primary tumor grows thanks to new vasculatization and, in time, adquires metastatic potential and spreads to other body sites, which causes metastasis and finally death. Cancer is caused by damage or mutations in the genetic material of the cells due to environmental or inherited factors. While surgery and radiotherapy are the primary treatment used for local and non-metastatic cancers, anti-cancer drugs (chemotherapy, hormone and biological therapies) are the choice currently used in metastasic cancers. Chemotherapy is based on the inhibition of the division of rapidly growing cells, which is a characteristic of the cancerous cells, but unfortunately, it also affects normal cells with fast proliferation rates, like the hair follicles, bone marrow and gastrointestinal tract cells, generating the characteristic side effects of chemotherapy. The indiscriminate destruction of normal cells, the toxicity of conventional chemotherapeutic Código de campo cambiado

show abstract

Section: Peptidic Targetingmentioning

confidence: 99%

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Pérez-Herrero

Fernández‐Medarde

2015

European Journal of Pharmaceutics and Biopharmaceutics

1,460

754

View full text Add to dashboard Cite

show abstract

“…The nanoparticle targeting ability was enhanced via strong affinity to various integrin-expressing cancer cells, and much less affinity to low integrin-expressing cancer cells. 133 Danhier et al showed that PEGylated PLGAbased nanoparticles grafted with the RGD peptide or an RGD peptidomimetic, targeted the tumor endothelium and would enhance the antitumor efficacy of paclitaxel. They observed that RGD-grafted nanoparticles were more associated with human umbilical vein endothelial cells in vitro by binding to α v β 3 integrin than were nontargeted nanoparticles, and they also demonstrated the targeting of RGD and RGD peptidomimetic-grafted nanoparticles to tumor vessels, as well as effective retardation of transplantable liver tumor growth and prolonged survival times in mice treated by paclitaxel-loaded RGD nanoparticles when compared with nontargeted nanoparticles.…”

Section: Ligand-receptor Interactionmentioning

confidence: 99%

Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents

Dinarvand¹,

Sepehri²,

Manoochehri³

et al. 2011

IJN

396

265

View full text Add to dashboard Cite

The effectiveness of anticancer agents may be hindered by low solubility in water, poor permeability, and high efflux from cells. Nanomaterials have been used to enable drug delivery with lower toxicity to healthy cells and enhanced drug delivery to tumor cells. Different nanoparticles have been developed using different polymers with or without surface modification to target tumor cells both passively and/or actively. Polylactide-co-glycolide (PLGA), a biodegradable polyester approved for human use, has been used extensively. Here we report on recent developments concerning PLGA nanoparticles prepared for cancer treatment. We review the methods used for the preparation and characterization of PLGA nanoparticles and their applications in the delivery of a number of active agents. Increasing experience in the field of preparation, characterization, and in vivo application of PLGA nanoparticles has provided the necessary momentum for promising future use of these agents in cancer treatment, with higher efficacy and fewer side effects.

show abstract

“…Activation of PHEMA-PLA to PHEMA-PLA-pNP was performed as described by Wang et al, 34 with some modifications. Briefly, 1.1 g of PHEMA-PLA was dissolved in 6 mL of chloroform by stirring, and then 0.5 g of pNP, 40 mg of 4-dimethylaminopyridine (dissolved in 6 mL of chloroform), and 1 mL of pyridine were added to the solution.…”

Section: Synthesis Of Phema-g-(pla-dppe) Copolymermentioning

confidence: 99%

“…11,12,14 In the present work, pNP was selected for activation of the PHEMA-PLA copolymer (Schema 1B) according to a previously reported method, with some changes. 34 The content of 4-nitrophenyl carbonate moieties could be determined during the reaction course. The degree of 4-nitrophenyl carbonate substitution could be controlled by adjusting the amount of chloroformate added.…”

Section: Dovepressmentioning

confidence: 99%

Construction of paclitaxel-loaded poly (2-hydroxyethyl methacrylate)-g-poly (lactide)- 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine copolymer nanoparticle delivery system and evaluation of its anticancer activity

Ma¹,

Wang²,

Jin³

et al. 2012

IJN

View full text Add to dashboard Cite

Background:There is an urgent need to develop drug-loaded biocompatible nanoscale packages with improved therapeutic efficacy for effective clinical treatment. To address this need, a novel poly (2-hydroxyethyl methacrylate)-poly (lactide)-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine [PHEMA-g-(PLA-DPPE)] copolymer was designed and synthesized to enable these nanoparticles to be pH responsive under pathological conditions. Methods: The structural properties and thermal stability of the copolymer was measured and confirmed by Fourier transform infrare d spectroscopy, nuclear magnetic resonance, and thermogravimetric analysis. In order to evaluate its feasibility as a drug carrier, paclitaxel-loaded PHEMA-g-(PLA-DPPE) nanoparticles were prepared using the emulsion-solvent evaporation method. Results:The PHEMA-g-(PLA-DPPE) nanoparticles could be efficiently loaded with paclitaxel and controlled to release the drug gradually and effectively. In vitro release experiments demonstrated that drug release was faster at pH 5.0 than at pH 7.4. The anticancer activity of the PHEMA-g-(PLA-DPPE) nanoparticles was measured in breast cancer MCF-7 cells in vivo and in vitro. In comparison with the free drug, the paclitaxel-loaded PHEMA-g-(PLA-DPPE) nanoparticles could induce more significant tumor regression. Conclusion: This study indicates that PHEMA-g-(PLA-DPPE) nanoparticles are promising carriers for hydrophobic drugs. This system can passively target cancer tissue and release drugs in a controllable manner, as determined by the pH value of the area in which the drug accumulates.

show abstract

Design of a Multifunctional PLGA Nanoparticulate Drug Delivery System: Evaluation of its Physicochemical Properties and Anticancer Activity to Malignant Cancer Cells

Abstract: The developed multifunctional nanoparticles hold potential to treat malignant integrin-expressing cancers.

Cited by 96 publications

References 44 publications

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents

Construction of paclitaxel-loaded poly (2-hydroxyethyl methacrylate)-g-poly (lactide)- 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine copolymer nanoparticle delivery system and evaluation of its anticancer activity

Contact Info

Product

Resources

About